We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Carcinoid Tumor Response to Fibroblast Interferon

David R. Strayer, MD; William A. Carter, MD; Isadore Brodsky, MD; Robert M. Curley, MD; Thomas Gain, MD
JAMA. 1984;251(13):1682-1683. doi:10.1001/jama.1984.03340370022016.
Text Size: A A A
Published online


To the Editor.—  Recently, Oberg et al1 reported symptomatic relief of carcinoid syndrome and decreases in tumor-associated metabolic products in six of nine patients receiving 3×106 to 6×106 units/day of leukocyte interferon intramuscularly for three months. Interestingly, with regard to possible effects on tumor growth, they were unable to demonstrate any histological changes or decreases in tumor size.Human interferons include proteins derived from fibroblasts and immune cells as well as those derived from leukocytes. The various molecular species differ both in regard to polypeptide sequence and carbohydrate content. Both in vitro2 and in vivo3 studies indicate that these various types of interferons can demonstrate tumor cell specificity.

Report of a Case.—  We recently treated with fibroblast interferon a 51-year-old man with biopsy-proved carcinoid of the rectum with multiple liver metastases. He had no symptoms of the carcinoid syndrome, and a 24-hour urine collection was


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.